张小雷

张小雷

教授

研究领域：1）癌症治疗的新靶点、新策略；
2）分子靶向药物、肿瘤免疫调节剂的发现与成药性研究；
3）能量代谢重构与肿瘤微环境在耐药和肿瘤免疫治疗中的作用及新机制探索。

办公电话： 020-39943044

联系邮箱： zhangxlei5@mail.sysu.edu.cn

联系方式

办公电话：020-39943044

电子邮箱：zhangxlei5@mail.sysu.edu.cn

办公地址：广州市大学城外环东路132号 bm11222宝马娱乐网站，邮编：510006

简单介绍

张小雷，中山大学“百人计划二期”引进人才，教授/博士生导师。主要从事肿瘤靶向治疗及药理毒理学研究。目前主持国家自然科学基金、广东省自然科学基金、广州市科技创新计划等多项科研项目。近5年来，以通讯作者在Cancer Research, JHO, Redox Biology, APSB, Theranostics, BJP,JMC等权威期刊发表论文20多篇， 国际PCT专利7项，获得发明专利授权22项。聚焦“难成药靶点”，作为主要贡献者发现了一系列转录因子STAT3抑制剂、G蛋白抑制剂、Kras抑制剂、腺苷受体A2AR靶向药物，及寡核苷酸药物分子。如WZ-2-033, BP-1-102, GQ127等，其中BP-1-102于2017年以1900万美元实现转让，目前进入临床I期研究，肿瘤免疫调节剂DX82正在推进临床试验许可及中美双报。

研究兴趣

1）抗肿瘤、抗衰老、眼科疾病创新药物发现与成药性研究 (Drug hunting for cancer、 aging and eye related diseases)

2）肿瘤微环境、治疗抵抗与干预新策略 (Tumor microenvironment and metabolism in drug resistance)

---欢迎有兴趣的同学报考，欢迎博士后加入，创新药创未来！

教育经历

吉林大学生命科学学院，本科 (BS)

吉林大学生命科学学院，硕士 (MS)

中佛罗里达大学医学院，博士 (PhD)

工作经历

2017.09-至今 bm11222宝马娱乐网站，副教授、教授、博士生导师

2018-2024 中山大学实验动物中心，副主任

2014-2017 美国佛罗里达医院转化医学研究所，研究科学家

2011-2014 美国Moffitt癌症中心，博士后、I级研究科学家

本科及研究生教学

本科课程：《人体解剖生理学》 、《人体解剖生理学实验》、《病理生理学》、《药理学》、《药理学实验》、《药理学案例分析》、《动物实验技术》、《实验动物学》

研究生课程：《细胞信号转导的分子基础与功能调控》、《药理学研究进展》、《药物筛选技术与进展》、《药物现代评价实验方法》、《医学实验动物学与技术》

社会/学术任职

中国药理学会表观遗传学专业委员会，委员

广东省药理学会药物毒理专业委员会，常务委员

广东省药理学会药物筛选与评价专业委员会，常务委员

中山大学实验动物管理与使用委员会（IACUC），委员

广东省药理学会抗炎免疫药理专业委员会，委员

广东省抗癌协会抗肿瘤药物专业委员会，委员

广东省药理学会肿瘤药理专业委员会，委员

广东省广东省抗癌协会肿瘤代谢专业委员会，委员

中西医结合学会实验医学专业委员会，常务委员

广东省精准医学应用学会疾病模型分会，委员

科研项目

  1. 国家自然科学基金面上项目，2023年1月-2026年12月，项目负责人
  2. 国家自然科学基金面上项目，2020年1月-2023年12月，项目负责人
  3. 广东自然科学基金面上项目，2024年1月-2026年12月，项目负责人
  4. 广东自然科学基金面上项目，2022年1月-2024年12月，项目负责人
  5. 广东自然科学基金面上项目，2019年10月-2022年9月，项目负责人
  6. 粤港澳联合创新项目：改善肿瘤免疫治疗敏感性创新药物的发现及临床前研究，2022年1月-2024年12月，中大方负责人
  7. 广州市基础与应用基础研究项目，2020年4月-2023年3月，项目负责人
  8. 中央高校基本科研业务费专项资金资助-中山大学青年教师培育项目，2019年1月-2022年12月，项目负责人
  9. 中山大学“百人计划二期”启动项目，2017年9月-2022年9月，项目负责人
  10. 横向项目：为临床试验药物提供药理学证据支撑  HT-99982022-020n，HT-99982023-029n，HT-99982023-029n，项目负责人
  11. 广东省重点领域研发计划-岭南中草药活性化合物库的构建及重大疾病候选药物发现，800万，2020年1月-2023年12月，参与人
  12. 广州市科技创新计划重点项目，基于胃癌分子可视化示踪的精准外科新技术及多组合融合的创新综合治疗研究，500万， 2022.01-2025.12，参与人
  13. 广州市科技创新计划重点项目，靶向转录因子STAT3 特异性抗肿瘤候选药物研发 2021年1月-2023年12月，100万参与人
  14. 吉林省科技发展-重点研发项目，一种新型靶向肿瘤免疫关键调控通路抑制剂的开发及临床前评价研究，2020年1月-2023年12月，子课题负责人
  15. 吉林省科技发展-重点研发项目，抗肿瘤候选药物的成药性评价及临床前研究，2020年1月-2023年12月，子课题负责人
  16. 广东省研究生教育创新计划-示范课程建设，2022SFKC005，项目负责人

学术论文(Publications)&发明专利(Patents)

2019年至今,国家发明专利及PCT专利 (Patents)

  1. 国家发明专利申请：一种苯并吡啶类化合物及其制备方法与应用，202311149238.6
  2. 国家发明专利授权：一种喹啉类SNX3抑制剂在制备抗心力衰竭组合物中的应用，专利号：ZL 202310141309.1 
  3. 国家发明专利授权：一种肾清除型双通道光学纳米探针及其制备方法和应用，专利号：ZL 202211596211.7 
  4. 国际PCT优先权：Use of Boric Acid Small Molecule Compound in Preparation of Drugs for Enhancing Curative Effect of Immune Checkpoint Inhibitor and Treating Leukemia，WO 2023245847A1
  5. 国家发明专利授权：一种苯并咪唑并吡嗪-3-甲酰胺化合物及其制备方法与应用，专利号： ZL 2022109687659 
  6. 国际PCT优先权：1-Aminobenzo[4,5]Midazo[1,2-a]Pyrazine-3-Formamide Compound, and Preparation Therefor and Use Thereof，WO2023130701
  7. 国际PCT优先权：Benzoimidazo Pyrazine-3-Carboxamide Compound Targeting A2A and Anti-tumor Immunological Funcation Thereof, WO 2023165165A1 
  8. 国家发明专利授权：一种硼酸类小分子化合物在制备增强免疫检查点抑制剂疗效及治疗白血病药物中的应用，专利号：ZL 202210713434.0
  9. 国际PCT优先权：Boric Acid Compound, Preparation Method and Use Thereof，WO2023168851A1
  10. 国家发明专利授权：一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用，ZL 202210611813.9
  11. 国家发明专利授权：嘧啶并吡咯类KRAS抑制剂及其制备方法与应用，专利号：ZL 202210578996.9
  12. 国际PCT优先权：A series of the oligonucleotide RNA molecules and their applications in anti-cancer drug development，WO 2023029489A1
  13. 国际PCT优先权：A derivative of nitrofuran molecule and acts as a ferroptosis inducer and applications in overcoming chemoresistance of gastric cancer, WO 2022218362A1
  14. 国家发明专利授权：靶向A2A的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能，专利号：ZL 202210200549.X 
  15. 国家发明专利授权：1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用，专利号：ZL 202210018141.0
  16. 国家发明专利授权：一种硼酸化合物制备方法及用途，专利号：ZL 2022102289627
  17. 国家发明专利授权：一种寡核苷酸RNA双链分子及其在制备治疗恶性肿瘤药物中的应用，ZL 202111034572.8
  18. 国家发明专利授权：含环丙烷结构的联苯类衍生物及其制备方法和应用，专利号：ZL  202111364348.5
  19. 国家发明专利授权：硝基呋喃类化合物、药物组合物及其制备方法和用途，ZL 202110407970.3 
  20. 国际PCT优先权：Imidazo Pyridine Compound, Pharmaceutical Composition Containing the Compound, Preparation Method Therefor, and Use Thereof，WO 2021088265A1 
  21. 国家发明专利授权：一种硝基呋喃类小芬化合物在制备诱导铁死亡和/或减缓胃癌化疗耐药药物中的应用 专利号：ZL 202110407948.9 
  22. 国家发明专利授权：一种3-芳基香豆素类衍生物及其制备方法和用途，专利号：ZL 202110223478.0
  23. 国家发明专利授权：一种取代吡啶并咪唑类化合物及其在制备治疗恶性肿瘤疾病药物中的应用，专利号：ZL 202010245491.1
  24. 国家发明专利授权：一种四氢咪唑[1,2-a]吡嗪类化合物、组合物及其制备方法与应用，专利号：ZL 202011327191.4 
  25. 国家发明专利授权：一种小分子STAT3抑制剂WZ-2-033及其在制备治疗乳腺癌和胃癌中的应用，专利号：ZL 202010629937.0 
  26. 国家发明专利授权：一种吡啶并咪唑类STAT3抑制剂在制备延缓或逆转TKI获得性耐药药物中的应用，专利号：ZL 202010257389.3 
  27. 国家发明专利授权：咪唑并吡啶类化合物、包含该化合物的药物组合物及其制备方法和用途, 专利号：ZL 201911070864.X
  28. 国家发明专利授权：一种喹啉类STAT3特异性抑制剂及其制备方法和应用, 专利号：ZL 201910300532.X 
  29. 国家发明专利授权：一种四氢异喹啉类衍生物及其合成方法和应用, 专利号：ZL 201911082947.0 
  30. 国家发明专利授权：一种含芳醚取代恶唑烷酮羧酸酯类衍生物及其制备方法和应用，专利号：ZL 201910065130.6

2018年至今, 学术论文 (Selected Publications)

  1. Ziyou Lin, Jingwei Li, Jian Zhang, Weineng Feng, Jiaye Lu, Xiaofan Ma, Wen Ding, Shumin Ouyang, Jinjian Lu, Peibin Yue, Guohui Wan, Peiqing Liu, Xiaolei Zhang*. Metabolic reprogramming driven by IGF2BP3 promotes acquired resistance to EGFR-TKIs in non-small lung cancer. Cancer Research. 2023 Jul 5;83(13):2187-2207. (中科院一区， IF=13.31 )
  2. Jianshan Mo, Lin Deng, Keren Peng, Shumin Ouyang, Wen Ding, Linlin Lou, Ziyou Lin, Jianzheng Zhu, Jingwei Li, Qiyi Zhang, Pengyan Wang, Yuanzhen Wen, Xiaobing Chen, Peibin Yue, JinJian Lu, Kai Zhu, Yongjiang Zheng*, Yuanxiang Wang*, Xiaolei Zhang *. Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia. Journal of Hematology & Oncology. 2023 Feb 27;16(1):15. (中科院一区，IF=25.56)
  3. Jiaye Lu, Jingwei Li, Ziyou Lin, Huaxuan Li, Linlin Lou, Wen Ding, Shumin Ouyang, Wu Yonghui, Yuanzhen Wen, Xiaobing Chen, Peibin Yue, Yuanxiang Wang, Jinjian Lu, Peiqing Liu, Jinjian Lu*,Jian Zhang*, Weineng Feng*, Xiaolei Zhang*. Reprogramming of TAMs by STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer. Cancer Letters. 2023 May 4;564:216205.  (中科院一区，IF=9.67)
  4. Tongfei Jin, Zhijing Zhang, Zhenghui Kang, Jianshan Mo, Xiaotong Yue, Ziyou Lin, Xiang Fu, Chang Liu, Hang Ma, Xiaolei Zhang*, Wenhao Hu*.Discovery and Optimization of Novel Biphenyl Derivatives BearingCyclopropyl Linkage as Potent Programmed Cell Death-1/ProgrammedCell Death-Ligand 1 Inhibitors. J Med Chem. 2023 May 25;66(10):6811-6835.. (中科院一区，IF=8.04 )
  5. Shumin Ouyang, Huaxuan Li, Linlin Lou, Qiuyao Huang, Zhenhua Zhang, Jianshan Mo, Min Li, Jiaye Lu, Kai Zhu, Yunjie Chu, Wen Ding, Jianzheng Zhu, Ziyou Lin, Lin Zhong, Junjian Wang, Peibin Yue, James Turkson, Peiqing Liu*, Yuanxiang Wang*, Xiaolei Zhang*. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biology. 2022, (52) 102317 (中科院一区， IF=10.79 )
  6. Yang Ge, Jun-Jie Deng, Jianzheng Zhu, Lu Liu, Shumin Ouyang, Zhendong Song, Xiaolei Zhang*, Xiao-Feng Xiong*, Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma, Acta Pharmaceutica Sinica B, 2022, Aug;12(8):3326-3340 (中科院一区，IF=14.90 )
  7. Qiyi Zhang, Wen Ding, Jianshan Mo, Shumin Ouyang, Ziyou Lin, Keren Peng, Guopin Liu, Jinjian Lu, Peibin Yue, Jinping Lei, Yandong Wang*, Xiaolei Zhang*. Novel STAT3 Oligonucletide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma. Acta Pharmacol Sin. 2024 Aug;45(8):1701-1714 (中科院一区， IF=7.19)
  8. Lin Deng, Jianshan Mo, Yi Zhang, Keren Peng, Huaxuan Li, Shumin Ouyang, Zongbo Feng, Wei Fang, Jianwei Wei, Deqin Rong, Xiaolei Zhang*, Yuanxiang Wang*. Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3.  J Med Chem. 2022 Oct 13;65(19):13094-13111(中科院一区，IF=8.04 )
  9. Shuhao Liu, Shuhao Liu, Wen Ding, Weifeng Huang, Zhijing Zhang, Yinfeng Guo, Qiyi Zhang, Linna Wu, Yukai Li, Rui Qin, Jiahao Li, Taoda Shi*, Xiaolei Zhang*, Jinping Lei*, and Wenhao Hu*. Discovery of Novel Benzo[4,5]imidazo[1,2-a]pyrazin-1-amine-3-amide-one Derivatives as Anticancer Human A2A Adenosine Receptor Antagonists. J. Med. Chem. 2022, Jul 14;65(13):8933-8947 (中科院一区，IF=8.04 )
  10. Huaxuan Li , Shumin Ouyang , Yi Zhang , Keren Peng , Wei Fang, Zhiqing Liu, Chang-Yun Wang , Xiaolei Zhang*, Yuanxiang Wang*. Structural optimization of Imidazo[1, 2-a]pyridine derivatives for the treatment of gastric cancer via STAT3 signaling pathway. Eur J Med Chem. 2022, 244,114858  (中科院一区， IF=7.09 )
  11. Zhendong Song, Linlin Lou, Guangjin Fan, Lu Liu, Yang Ge, He Liu, Albert S.C. Chan, Xiaolei Zhang*, Xiaofeng Xiong*. Identification of Novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C  Inhibitors with Anticancer Effects. Eur J Med Chem. 2022, Nov 9th, doi.org/10.1016/ j.ejmech.2022.114907  (中科院一区， IF=7.09 )
  12. Shumin Ouyang, Qiyi Zhang, Linlin Lou, Kai Zhu, Zeyu Li, Peiqin Liu*, Xiaolei Zhang*. The double-edged sword of SIRT3 in cancer and its therapeutic applications. Frontiers in Pharmacology, 2022, April 27th, (13):871560 ( 中科院二区，IF=5.99 )
  13. Huanxin Xue, Jiaye Lu, Hongwei Yan, Ju Huang, Hai-Bin Luo, Man Shing Wong, Yuqi Gao*, Xiaolei Zhang*, Lei Guo*. γ-Glutamyl transpeptidase–activated indole-quinolinium based cyanine as a fluorescence turn-on nucleolus-targeting probe for cancer cell detection and inhibition. Talanta，2022 Jan 15;237:122898 (中科院二区， IF=6.56 )
  14. Guangjin Fan, Linlin Lou, Zhendong Song*, Xiaolei Zhang*, Xiao-Feng Xiong*. Targeting mutated GTPase KRAS in tumor therapies. Eur J Med Chem. 2021; 226:113816  (中科院一区， IF=7.09 )
  15. Yan Zhong, Lin Deng, Shuo Shi, Qiu-yao Huang, Shu-min Ou-Yang, Jian-shan Mo, Kai Zhu, Xin-ming Qu, Pei-qing Liu*, Yuan-xiang Wang* and Xiao-lei Zhang*.The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts. Acta Pharmacol Sin. 2022 Apr;43(4):1013-1023 (中科院一区， IF=7.19)
  16. Qiuyao Huang, Yan Zhong, Bingbing Li, Shumin Ouyang, Lin Deng, Jianshan Mo, Shuo Shi, Nan Lv, Ruibo Wu, Peiqing Liu, Wenhao Hu, Xiaolei Zhang* Yuanxiang Wang*. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). Eur J Med Chem. 2021;221:113525. (中科院一区， IF=7.09 )
  17. Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P*, Wang Y*, Zhang X*. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 2021; 11(2):824-840. (中科院一区， IF=11.60 )
  18. Yang Ge, Shuo Shi, Jun-Jie Deng, Xue-Ping Chen, Zhendong Song, Lu Liu, Linlin Lou, Xiaolei Zhang*, Xiao-Feng Xiong*.Design, Synthesis, and Evaluation of Small Molecule Gαq/11 Protein Inhibitors for the Treatment of Uveal Melanoma. J Med Chem. 2021,64(6):3131-3152. (中科院一区， IF=8.04 )
  19. Xiao-lei Zhang#, Zhuo-ming Li#, Jian-tao Ye, Jing Lu, Lingyu Linda Ye, Chun-xiang Zhang, Pei-qing Liu* and Dayue D Duan*. Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. Acta Pharmacol Sin. 2020 Nov; 41(11): 1377–1386. (中科院一区， IF=7.19 )
  20. Qiuyao Huang, Yan Zhong, Hui Dong, Qiyao Zheng, Shuo Shi, Kai Zhu, Xinming, Wenhao Hu, Xiaolei Zhang*, Yuanxiang Wang*. Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go? Eur J Med Chem. 2020 ;187: 111922.  (中科院一区， IF=7.09 )
  21. Jingyan Li , Junying Huang,  Jing Lu, Zhen Guo, Zhuoming Li, Hui Gao, Panxia Wang, Wenwei Luo, Sidong Cai, Yuehuai Hu, Kaiteng Guo, Luping Wang, Zhenzhen Li, Minghui Wang, Xiaolei Zhang*, Peiqing Liu*. Sirtuin 1 represses PKC-ζ activity through regulating interplay of acetylation and phosphorylation in cardiac hypertrophy, British Journal of Pharmacology, 2019, 176(3):416-435  (中科院药学一区， IF=9.47 )
  22. Lei Sun, Ruonian Liu, Zong-Jian Wu, Zheng-Yu Liu, Arabella H Wan, Shijia Yan, Chuwei Liu, Heng Liang, Min Xiao, Nan You, Yawen Lou, Yuan Deng, Xianzhang Bu, Dongshi Chen, Jun Huang, Xiaolei Zhang, Dong-Ming Kuang, Guohui Wan*. Gastroenterology . 2024 Mar;166(3):466-4824. (中科院一区， IF=16.60 )
  23. 张芷菁, 张启怡, 金祖翼, 朱凯, 丁文*, 张小雷*. 靶向腺苷A2A受体的肿瘤免疫治疗研究进展(Progress for targeting adenosine A2A receptors in cancer immunotherapy), 药学学报 Acta Pharmaceutica Sinica, 2022, 57(9):2557−2569

  24. Ziyou Lin; Arabella H Wan; Lei Sun; Heng Liang; Yi Niu; Yuan Deng; Shijia Yan; Qiao-Ping Wang; Xianzhang Bu; Xiaolei Zhang; Kunhua Hu*; Guohui Wan*; Weiling He*. N6-methyladenosine demethylase FTO enhances chemo-resistance in colorectal cancer through SIVA1-mediated apoptosis. Molecular Therapy, 2023 Feb 1;31(2):517-534 (中科院一区， IF=12.91 )

  25. Wang B, Wan AH, Xu Y, Zhang RX, Zhao BC, Zhao XY, Shi YC, Zhang X, Xue Y, Luo Y, Deng Y, Neely GG, Wan G*, Wang QP*. Identification of indocyanine green as a STT3B inhibitor against mushroom α-amanitin cytotoxicity. Nat Commun. 2023 May 16;14(1):2241. (中科院一区， IF=16.60 )

  26. Jian Li, Yang Ge, Junxiang Huang, Kristan Stromgaard, Xiaolei Zhang, Xiaofeng Xiong*. Heterotrimeric G Proteins as Therapeutic Targets in Drug Discovery. J Med Chem. 2020 May 28;63(10):5013-5030 (中科院一区，IF=8.04 )

  27. Wenjing Yu, Yuehuai Hu, Zhiping Liu, Kaiteng Guo, Dinghu Ma, Mingxia Peng, Yuemei Wang , Jing Zhang, Xiaolei Zhang, Panxia Wang, Jiguo Zhang, Peiqing Liu*, Jing Lu*. Sorting nexin 3 exacerbates doxorubicin-induced cardiomyopathy via regulation of TFRC-dependent ferroptosis. Acta Pharm Sin B. 2023 Dec;13(12):4875-4892. (中科院一区，IF=14.90 )

  28. 石硕、朱凯、熊晓峰*、张小雷*。Gq 突变在葡萄膜黑色素瘤中的作用及其抑制剂研究进展 （Study of Gq mutations and their inhibitors in uveal melanoma）。药学学报 Acta Pharmaceutica Sinica 2020, 55(7): 1382 −1392

  29. Mu-Yang Huang, Yu-Chi Chen, Wen-Yu Lyu, Xin-Yu He, Zi-Han Ye, Can-Yu Huang, Xin-Ling He, Xiuping Chen, Xiaobing Chen, Baoxian Zhang, Guoyin Kai, Xiaolei Zhang, Ting Li, Mingqing Huang, Jin-Jian Lu*. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10. Pharmacol Res. 2023 Dec:198:106988. doi: 10.1016/j.phrs.2023.106988  ( 中科院药学一区，IF=9.30 )

  30. Chun-Cao Xu, Yi-Fan Lin, Mu-Yang Huang, Xiao-Lei Zhang, Pei Wang, Ming-Qing Huang, Jin-Jian Lu*. Paraptosis: a non-classical paradigm of cell death for cancer therapy. Acta Pharmacol Sin. 2024 Feb;45(2):223-237.(中科院一区， IF=7.19 )

  31. Jing Lu, Suowen Xu, Yuqing Huo, Duanping Sun, Yuehuai Hu, Junjian Wang, Xiaolei Zhang, Panxia Wang, Zhuoming Li, Mengya Liang, Zhongkai Wu*, Peiqing Liu*. Sorting nexin 3 induces heart failure via promoting retromer-dependent nuclear trafficking of STAT3. Cell death and differentiation. 2021 Oct;28(10):2871-2887  (中科院一区， IF=15.83 )

  32. Jianwei Zheng, Junfeng Wang, Qian Wang, Hongye Zou, Hong Wang, Zhenhua Zhang, Jianghe Chen, Qianqian Wang, Panxia Wang, Yueshan Zhao, Jing Lu, Xaiolei Zhang, Songtao Xiang, Haibin Wang, Jinping Lei, Hong-Wu Chen, Peiqing Liu, Yonghong Liu*, Fanghai Han*, Junjian Wang*. 2020 Targeting castration-resistant prostate cancer with a novel RORγ antagonist elaiophylin, Acta Pharmaceutica Sinica B, 2020,10(12), 2313-2322  (中科院一区， IF=14.90 )

  33. Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, Zhang X, Bu X, He W*, Wan G*. RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. The EMBO Journal. 2020 Jun 17;39(12):e103181.  (中科院一区， IF=14.01 )

  34. Yuting Zhang, Weiting Lu, Xiaolei Zhang, Jing Lu, Suowen Xu, Shaorui Chen, Zhi Zhong, Ting Zhou, Quan Wang, Jianwen Chen*, Peiqing Liu*. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacol Res. 2019 Sep;147:104307  ( 中科院药学一区，IF=9.30 )

  35. Michelle B. Trevino#, Xiaolei Zhang#, Robert A. Standley, Miao Wang,Xianlin Han, Felipe C. G. Reis, Muthu Periasamy, Gongxin Yu, Daniel P. Kelly, Bret H. Goodpaster,Rick B. Vega,1,2 and Paul M. Coen*.Loss of mitochondrial energetics is associated with poor recovery of muscle function but not mass following disuse atrophy. Am J Physiol Endocrinol Metab. 2019 Nov 1; 317(5): E899–E910.

  36. Xiaolei Zhang, Trevino MB, Wang M, Gardell SJ, Ayala JE, Han X, Kelly DP, Goodpaster BH, Vega RB, Coen PM. Impaired Mitochondrial Energetics Characterize Poor Early Recovery of Muscle Mass Following Hind Limb Unloading in Old Mice, J Gerontol A Biol Sci Med Sci. 2018,73(10):1313-1322 (中科院一区， IF=6.59)

  37. Stephen J Gardell, Xiaolei Zhang, Nidhi Kapoor, Christopher Petucci, Paul M Coen. Metabolomics Analyses of Muscle Atrophy Induced by Hind Limb Unloading. Methods Mol Biol. 2019;1996:297-309

  38. Giovanna Distefano, Robert A. Standley, Xiaolei Zhang, Elvis A. Carnero, Fanchao Yi, Heather H. Cornnell, Paul M. Coen*. Physical activity unveils the relationship between mitochondrial energetics, muscle quality, and physical function in older adults. J Cachexia Sarcopenia Muscle. 2018 Apr; 9(2): 279–294. (中科院一区， IF=12.06 )

专著 （Book Chapter）

  1. Stephen J. Gardell, Xiaolei Zhang, Nidhi Kapoor, Christopher Petucci, and Paul M. Coen. Metabolomics: Methods and Protocols, Springer，2019, 297-310
  2. Hui Zhou, Yinqiu Cui, Haijing Wang, Yue Xu, Xiaolei Zhang.  An Introduction to Molecular Archaeology. 科学出版社(Science Press)  in 2008 Chapter 9 and 10 (Chapter 9: Dating mining and biostatistics analysis of ancient DNA information, Chapter 10: The application of bioinformatics and statistics tools in ancient DNA research)

 

2018年之前，学术论文 （Selected Publications）

  1. Xiaolei Zhang, Peibin Yue , Brent D.G. Page , Tianshu Li , Wei Zhao , Andrew T. Namanja , David Paladino , Jihe Zhao , Yuan Chen , Patrick T. Gunning , James Turkson . Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc. Natl. Acad. Sci. USA (PNAS) 2012, 109 (24): 9623-9628 (中科院一区， IF=12.78)
  2. Zhang X, Blaskovich MA, Forinash KD, Sebti SM.  Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours. British Journal of Cancer. 2014,111(5):894-902 (中科院一区， IF=9.07 )
  3. Xiaolei Zhang, Ying Sun, Roberta Pireddu, Hua Yang, Murali K. Urlam , Harshani Lawrence , Wayne C. Guida , Nicholas J. Lawrence, Said M Sebti. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Research 2013, 73(6):1922-1933  (中科院一区， IF=13.31 )
  4. Teng P#, Zhang X#, Wu H, Qiao Q, Sebti SM, Cai J. Identification of novel inhibitors that disrupt STAT3-DNA interaction from a γ-AApeptide OBOC combinatorial library. Chem Commun (Camb). 2014 Aug 14;50(63):8739-42. (#Co-first Author)  ( IF=6.22 )
  5. Zhang X, Yue P, Fletcher S, Zhao W, Gunning PT, Turkson J. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010, 79(10):1398-409. ( IF=6.10)
  6. Peibin Yue, Xiaolei Zhang, David Paladion, James Turkson. Hyperactive EGF receptor and Stat3 signaling promote enhanced colony-forming ability motility and migration of Cisplatin-resistant ovarian cancer cells. Oncogene 2012, 31(18):2309-22 (中科院一区， IF=8.76 )
  7. Astha Malhotra, Xiaolei Zhang, James Turkson, Swadeshmukul Santra. Buffer-Stable Chitosan–Polyglutamic Acid Hybrid Nanoparticles for Biomedical Applications.Macromolecular Bioscience 2013 May;13(5):603-13 ( IF=5.86)
  8. Awet Tecleab, Xiaolei Zhang and Said M. Sebti Ral GTPase down regulation stabilizes and reactivates p53 to inhibit malignant transformation. Journal of Biological Chemistry 2014 Nov 7;289(45):31296-309 ( IF=5.49)
  9. Mitra, Rajendra; Doshi, Mona; Zhang, Xiaolei; Tyus, Jessica; Bengtsson, Niclas; Fletcher, Steven; Page, Brent; Turkson, James; Gesquiere, Andre; Gunning, Patrick; Walter, Glenn; Santra, Swadeshmukul. An activatable multimodal/multifunctional nanoprobe for direct imaging of intercellular drug delivery.  Biomaterials. 2012, 33(5):1500-8 (中科院一区， IF=15.30 )
  10. Fletcher S, Singh J, Zhang X, Yue P, Page BD, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J, Gunning PT. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem. 2009, 10(12):1959-64 ( IF=3.46 )
  11. Fletcher S, Page BD, Zhang X, Yue P, Li ZH, Sharmeen S, Singh J, Zhao W, Schimmer AD, Trudel S, Turkson J, Gunning PT. Antagonism of the Stat3-Stat3 Protein Dimer with Salicylic Acid Based Small Molecules. ChemMedChem. 2011 6(8):1459-70 ( IF=3.54 )
  12. Drewry JA, Fletcher S, Yue P, Marushchak D, Zhao W, Sharmeen S, Zhang X, Schimmer AD, Gradinaru C, Turkson J, Gunning PT. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun (Camb). 2010 ,;46(6):892-4 ( IF=6.22 )
  13. Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett. 2011, 21(18):5605-9 ( IF=2.82 )
  14. Vijay M. Shahani, Peibin Yue, Sina Haftchenary, Wei Zhao, Julie L. Lukkarila, Xiaolei Zhang, Daniel Ball, Christina Nona, Patrick T. Gunning, and James Turkson. Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies  ACS Med. Chem. Lett., 2011 ,2(1):79-84. ( IF=4.63 )
  15. Shahani VM, Yue P, Fletcher S, Sharmeen S, Sukhai MA, Luu DP, Zhang X, Sun H, Zhao W, Schimmer AD, Turkson J, Gunning PT. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorg Med Chem. 2011, 19(5):1823-38 ( IF=3.64 )
  16. Murali K. Urlam, Roberta Pireddu, Yiyu Ge, Xiaolei Zhang, Ying Sun,Harshani R. Lawrence, Wayne C. Guida,Saïd M. Sebti,Nicholas J. Lawrence. Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors. Medical Chemistry Communications 2013 Jun;4(6):932-941
  17. Y. Changchun, X. Li, Z. Xiaolei, Z. Hui, Z. Hong. Genetic analysis on Tuoba Xianbei remains excavated from Qilang mountain cemetery in Qahar Right Wing Middle Banner of Inner Mongolia. FEBS Letters, 2006, 580(26): 6242–6246
  18. Lu Han, Dawei Cai, Huixin Yu, Xiaolei Zhang, Hui Zhou, Hong Zhu. Mitochondria DNA analysis of ancient sheep from Inner Mongolia in the warring state period. Progress in Natural Sciences (China) 2009, 19(10):1049-1055
  19. Da-Wei Cai, Lu Han, Xiao-Lei Zhang, Hui Zhou . DNA analysis of archaeological sheep remains from China . Journal of Archaeological Sciences, 2007, 34(9):1347-1355
  20. YU Chang-Chun, XIE Li, ZHANG Xiao-lei, ZHOU Hui, ZHU Hong. Genetic Analyses on the Affinities between Tuoba Xianbei and Xiongnu Population. HEREDITAS (Beijing), 2007,29(10):1223-1229
  21. YU Chang-chun, LI Wen-rong, XIE Li, ZHANG Xiao-lei, ZHOU Hui, ZHU Hong. Genetic Analysis on Mitochondrial DNA of Xibe Population in Xinjiang. Journal of Jilin University (Science Edition), 2007,45(5):485-489
  22. Yue Xu, Xiaolei Zhang, Yinqiu Cui, Quanchao Zhang, Hui Zhou, Hong Zhu. Genetic Structure Analysis of Human Remains from Khitan Noble Necropolis. Chem. Res. Chinese U. 2006, 22(2):123-128
  23. Fu Yuqin, Xu Xuelian, Zhang Xiaolei, Zhouhui, Zhu Hong. Phylogenetic analysis of mtDNA from the ancient Human of Yuan Dynasty in Inner-Mongolia in China . Chem. Res. Chinese U. 2006, 22(2):177 -180
  24. WANG Haijing, LIU Weiqiang, FU Yuqin, ZHANG Xiaolei, et al. Molecular biological analysis of remains from Jiangjungou cemetery in Inner Mongolia . Progress in Natural Science. 2006, 16(7): 894-898
  25. Yu Chang-chun, Xie Li, Zhang Xiao-lei, Zhou Hui, Zhu Hong. Analyses on the genetic affinities between Tuoba Xianbei and minorities from northern China . Journal of Northerneast Normal University (Natural Science Edition), 2007, 39(4):121-126
  26. Zhang Xiao-lei，Cui Yin-qiu, Lv Hui-ying, Zhou Hui. Application of Phylogenetic Analysis in Ancient DNA Research. Journal of Jilin University (Science Edition), 2005, 43(5):696-701
  27. Xu Yue, Zhang Xiao-lei, Zhang Quan-chao, Cui Yin-qiu, Zhou Hui. Mitochondrial DNA Analysis of Turki Human Remain. Journal of Jilin University (Medicine Edition), 2006, 32(2): 248 - 250
  28. Xu Yue, Zhang Xiao-lei, Zhang Quan-chao, etal. Genetic Analysis between Ancient Khitan Population and Modern Daur Population. Journal of Jilin University (Science Edition), 2006, 44(6):997-1000